These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 11443224)

  • 1. Rapid communication: inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes.
    Koshiyama H; Shimono D; Kuwamura N; Minamikawa J; Nakamura Y
    J Clin Endocrinol Metab; 2001 Jul; 86(7):3452-6. PubMed ID: 11443224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes.
    Minamikawa J; Tanaka S; Yamauchi M; Inoue D; Koshiyama H
    J Clin Endocrinol Metab; 1998 May; 83(5):1818-20. PubMed ID: 9589700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of pioglitazone on carotid intima-media thickness and arterial stiffness in type 2 diabetic nephropathy patients.
    Nakamura T; Matsuda T; Kawagoe Y; Ogawa H; Takahashi Y; Sekizuka K; Koide H
    Metabolism; 2004 Oct; 53(10):1382-6. PubMed ID: 15375799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term effects of pioglitazone on carotid atherosclerosis in Japanese patients with type 2 diabetes without a recent history of macrovascular morbidity.
    Yamasaki Y; Katakami N; Furukado S; Kitagawa K; Nagatsuka K; Kashiwagi A; Daida H; Kawamori R; Kaku K
    J Atheroscler Thromb; 2010 Nov; 17(11):1132-40. PubMed ID: 20686324
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study.
    Pfützner A; Marx N; Lübben G; Langenfeld M; Walcher D; Konrad T; Forst T
    J Am Coll Cardiol; 2005 Jun; 45(12):1925-31. PubMed ID: 15963388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pioglitazone vs glimepiride and carotid intima-media thickness.
    Giugliano D; Esposito K
    JAMA; 2007 Mar; 297(12):1315-6; author reply 1316-7. PubMed ID: 17392236
    [No Abstract]   [Full Text] [Related]  

  • 7. Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus: results from a controlled randomized study.
    Langenfeld MR; Forst T; Hohberg C; Kann P; Lübben G; Konrad T; Füllert SD; Sachara C; Pfützner A
    Circulation; 2005 May; 111(19):2525-31. PubMed ID: 15883215
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of glycemic and lipid response to pioglitazone treatment in Mexican-Americans and non-Hispanic Caucasians with type 2 diabetes.
    King AB; Armstrong DU; Chinnapongse S
    Diabetes Care; 2003 Jan; 26(1):245-6. PubMed ID: 12502690
    [No Abstract]   [Full Text] [Related]  

  • 9. The novel hypoglycemic agent YM440 normalizes hyperglycemia without changing body fat weight in diabetic db/db mice.
    Shimaya A; Kurosaki E; Nakano R; Hirayama R; Shibasaki M; Shikama H
    Metabolism; 2000 Mar; 49(3):411-7. PubMed ID: 10726922
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pioglitazone vs glimepiride and carotid intima-media thickness.
    Kida Y; Sato T
    JAMA; 2007 Mar; 297(12):1316; author reply 1316-7. PubMed ID: 17392237
    [No Abstract]   [Full Text] [Related]  

  • 11. Metformin or gliclazide, rather than glibenclamide, attenuate progression of carotid intima-media thickness in subjects with type 2 diabetes.
    Katakami N; Yamasaki Y; Hayaishi-Okano R; Ohtoshi K; Kaneto H; Matsuhisa M; Kosugi K; Hori M
    Diabetologia; 2004 Nov; 47(11):1906-13. PubMed ID: 15565373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus.
    Rosenblatt S; Miskin B; Glazer NB; Prince MJ; Robertson KE;
    Coron Artery Dis; 2001 Aug; 12(5):413-23. PubMed ID: 11491207
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pioglitazone-induced hepatic injury in a patient previously receiving troglitazone with success.
    Nagasaka S; Abe T; Kawakami A; Kusaka I; Nakamura T; Ishikawa S; Saito T; Ishibashi S
    Diabet Med; 2002 Apr; 19(4):347-8. PubMed ID: 11943013
    [No Abstract]   [Full Text] [Related]  

  • 14. Thiazolidinediones, peroxisome proliferator-activated receptor gamma agonists, regulate endothelial cell growth and secretion of vasoactive peptides.
    Fukunaga Y; Itoh H; Doi K; Tanaka T; Yamashita J; Chun TH; Inoue M; Masatsugu K; Sawada N; Saito T; Hosoda K; Kook H; Ueda M; Nakao K
    Atherosclerosis; 2001 Sep; 158(1):113-9. PubMed ID: 11500181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naive patients with type 2 diabetes mellitus.
    Herz M; Johns D; Reviriego J; Grossman LD; Godin C; Duran S; Hawkins F; Lochnan H; Escobar-Jiménez F; Hardin PA; Konkoy CS; Tan MH
    Clin Ther; 2003 Apr; 25(4):1074-95. PubMed ID: 12809958
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison in a clinical setting of the efficacy and side effects of three thiazolidinediones.
    King AB
    Diabetes Care; 2000 Apr; 23(4):557. PubMed ID: 10857952
    [No Abstract]   [Full Text] [Related]  

  • 17. Effects of insulin and oral anti-diabetic agents on glucose metabolism, vascular dysfunction and skeletal muscle inflammation in type 2 diabetic subjects.
    Joya-Galeana J; Fernandez M; Cervera A; Reyna S; Ghosh S; Triplitt C; Musi N; DeFronzo RA; Cersosimo E
    Diabetes Metab Res Rev; 2011 May; 27(4):373-82. PubMed ID: 21309063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Common polymorphisms of the peroxisome proliferator-activated receptor-gamma (Pro12Ala) and peroxisome proliferator-activated receptor-gamma coactivator-1 (Gly482Ser) and the response to pioglitazone in Chinese patients with type 2 diabetes mellitus.
    Hsieh MC; Lin KD; Tien KJ; Tu ST; Hsiao JY; Chang SJ; Lin SR; Shing SJ; Chen HC
    Metabolism; 2010 Aug; 59(8):1139-44. PubMed ID: 20045142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical evaluation of pioglitazone].
    Kobayashi M; Iwata M; Haruta T
    Nihon Rinsho; 2000 Feb; 58(2):395-400. PubMed ID: 10707564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and tolerability of pioglitazone in patients with type 2 diabetes mellitus: comparison with other oral antihyperglycaemic agents.
    Derosa G
    Drugs; 2010 Oct; 70(15):1945-61. PubMed ID: 20883052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.